Twist Bioscience (NASDAQ:TWST) CEO Emily Leproust Sells 5,001 Shares of Stock

Twist Bioscience Corporation (NASDAQ:TWST) CEO Emily Leproust sold 5,001 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $46.58, for a total value of $232,946.58. Following the sale, the chief executive officer directly owned 869,312 shares of the company’s stock, valued at approximately $40,492,552.96. The trade was a 0.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Twist Bioscience Stock Up 1.7%

Twist Bioscience stock opened at $47.92 on Friday. Twist Bioscience Corporation has a twelve month low of $23.30 and a twelve month high of $54.26. The company has a quick ratio of 3.33, a current ratio of 3.78 and a debt-to-equity ratio of 0.03. The company has a 50 day moving average of $36.54 and a 200-day moving average of $31.94. The stock has a market capitalization of $2.94 billion, a PE ratio of -37.24 and a beta of 2.24.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.02). The firm had revenue of $103.70 million for the quarter, compared to analyst estimates of $100.32 million. Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.The firm’s quarterly revenue was up 16.9% compared to the same quarter last year. On average, equities research analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

More Twist Bioscience News

Here are the key news stories impacting Twist Bioscience this week:

• Positive Sentiment: Company guidance was lifted, with coverage highlighting stronger demand tied to AI-related customers but also noting execution risks; the guidance boost is being read as evidence of improving end-market demand. Twist Bioscience Guidance Lift Puts AI Demand And Risks In Focus
• Positive Sentiment: An analyst price target was raised 20% to $48.35, signaling increased bullishness from at least one wall‑street watcher and supporting the recent share-price momentum. TWST price target increased by 20%
• Neutral Sentiment: A recent valuation piece assesses TWST after its run-up and discusses whether the current share price already reflects improved fundamentals and the guidance lift; useful for investors re-evaluating upside vs. valuation risk. Assessing Twist Bioscience Valuation
• Negative Sentiment: CEO Emily Leproust sold 5,001 shares at an average $46.58 (≈0.57% reduction in her stake). Insider sales by the CEO can spook investors even if they are routine. CEO sale filing
• Negative Sentiment: CAO Robert F. Werner reported larger sales: 7,000 shares at an average $45.65 (≈10.65% reduction in one filing) plus an earlier 175-share sale; these are meaningful reductions from a senior finance officer. CAO sale filing
• Negative Sentiment: Other insiders, including SVP Paula Green (1,194 shares) and insider Dennis Cho (1,099 shares), also sold stakes at ~ $46.58, adding to overall insider selling activity this week. SVP sale filing Insider sale filing

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on TWST. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a research note on Monday, December 29th. Robert W. Baird set a $50.00 price target on shares of Twist Bioscience in a research report on Tuesday. Evercore ISI lifted their price objective on shares of Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a research report on Tuesday. Barclays upped their target price on shares of Twist Bioscience from $39.00 to $50.00 and gave the company an “overweight” rating in a report on Tuesday. Finally, Stephens initiated coverage on Twist Bioscience in a report on Monday, November 3rd. They set an “overweight” rating and a $41.00 price target for the company. Seven investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $45.88.

Institutional Trading of Twist Bioscience

Hedge funds have recently added to or reduced their stakes in the company. Royal Bank of Canada grew its stake in shares of Twist Bioscience by 11.8% in the first quarter. Royal Bank of Canada now owns 40,373 shares of the company’s stock valued at $1,585,000 after acquiring an additional 4,254 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Twist Bioscience by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,310 shares of the company’s stock worth $2,765,000 after purchasing an additional 3,181 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Twist Bioscience by 4.2% during the first quarter. Goldman Sachs Group Inc. now owns 932,978 shares of the company’s stock worth $36,629,000 after purchasing an additional 37,577 shares during the period. Intech Investment Management LLC increased its holdings in shares of Twist Bioscience by 18.9% during the first quarter. Intech Investment Management LLC now owns 28,917 shares of the company’s stock worth $1,135,000 after purchasing an additional 4,591 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Twist Bioscience by 15.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock valued at $85,000 after buying an additional 302 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.